{"id":2179,"date":"2023-09-29T04:00:00","date_gmt":"2023-09-29T04:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/valberedning-i-xvivo-perfusion-ab-publ\/"},"modified":"2023-10-18T12:06:49","modified_gmt":"2023-10-18T12:06:49","slug":"valberedning-i-xvivo-perfusion-ab-publ","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ\/","title":{"rendered":"Valberedning i XVIVO Perfusion AB (publ)"},"content":{"rendered":"<div class=\"mfn-body\">\n<p>F\u00f6ljande personer har utsetts att ing\u00e5 i XVIVO Perfusions valberedning inf\u00f6r \u00e5rsst\u00e4mman 2024:<\/p>\n<p>Henrik Blomquist, utsedd av Bure Equity AB<br \/>Fredrik Stenkil, utsedd av Swedbank Robur Fonder AB<br \/>Thomas Ehlin, utsedd av Fj\u00e4rde AP-fonden<br \/>G\u00f6sta Johannesson, styrelsens ordf\u00f6rande<br \/>\u00a0<br \/>Utn\u00e4mningen har skett enligt den instruktion avseende principer f\u00f6r utseende av valberedning i bolaget som fastst\u00e4lldes vid \u00e5rsst\u00e4mman i XVIVO Perfusion AB (publ) den 27 april 2018. De aktie\u00e4gare som har utsett ledam\u00f6terna i valberedningen representerade sammanlagt 32,4 procent av samtliga aktier i bolaget per den 31 augusti 2023.<br \/>\u00a0<br \/>I valberedningens uppdrag ing\u00e5r att inf\u00f6r \u00e5rsst\u00e4mman 2024 bereda och l\u00e4mna f\u00f6rslag till (i) val av ordf\u00f6rande vid st\u00e4mman, (ii) beslut om antalet styrelseledam\u00f6ter, (iii) val av och beslut om arvoden till styrelsens ordf\u00f6rande och styrelseledam\u00f6terna, (iv) val av och beslut om arvoden till revisor och (v) beslut om ny valberedningsprocedur f\u00f6r det fall valberedningen anser att det \u00e4r n\u00f6dv\u00e4ndigt.<br \/>\u00a0<br \/>\u00c5rsst\u00e4mma i XVIVO Perfusion AB (publ) kommer att h\u00e5llas den 25 april 2024 i G\u00f6teborg. Aktie\u00e4gare som vill l\u00e4mna f\u00f6rslag till valberedningen \u00e4r v\u00e4lkomna att g\u00f6ra det i god tid f\u00f6re \u00e5rsst\u00e4mman s\u00e5 att valberedningen hinner beakta f\u00f6rslaget. F\u00f6rslag ska s\u00e4ndas till XVIVO Perfusion AB (publ), Att: Valberedningen, Gemenskapens gata 9, 431 53 M\u00f6lndal.<\/p>\n<p>G\u00f6teborg 30 september 2023<br \/>XVIVO Perfusion AB (publ)<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-fb9cf3b124f9\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/strong><\/p>\n<hr\/>\n<p>Christoffer Rosenblad, VD, +46 73 519 21 59, e-post: christoffer.rosenblad@xvivogroup.com<br \/>Kristoffer\u00a0Nordstr\u00f6m,\u00a0CFO, +46 73 519 21 64, e-post:\u00a0kristoffer.nordstrom@xvivogroup.com<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-da5f5ee9f867\">\n<p><strong class=\"mfn-heading-1\">Om oss<\/strong><\/p>\n<hr\/>\n<p>XVIVO grundades 1998 och \u00e4r ett medicintekniskt f\u00f6retag dedikerat till att f\u00f6rl\u00e4nga livet f\u00f6r donerade organ s\u00e5 att transplantationsteam runt om i v\u00e4rlden kan r\u00e4dda fler liv. V\u00e5ra l\u00f6sningar g\u00f6r det m\u00f6jligt f\u00f6r ledande kliniker och forskare att t\u00e4nja p\u00e5 gr\u00e4nserna f\u00f6r transplantationsmedicin.\u00a0XVIVO har sitt huvudkontor i G\u00f6teborg och har kontor och forskningsanl\u00e4ggningar p\u00e5 tv\u00e5 kontinenter. Bolaget \u00e4r noterat p\u00e5 Nasdaq Stockholm\u00a0och handlas under symbolen XVIVO. Mer information finns att l\u00e4sa p\u00e5 hemsidan www.xvivogroup.com\/us<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/e78ac5d8-42e1-46b9-ac23-be04c89b9316\/valberedning-i-xvivo-perfusion-ab-publ.pdf\" rel=\"noopener\" target=\"_blank\">Valberedning i XVIVO Perfusion AB (publ)<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>F\u00f6ljande personer har utsetts att ing\u00e5 i XVIVO Perfusions valberedning inf\u00f6r \u00e5rsst\u00e4mman 2024: Henrik Blomquist, utsedd av Bure Equity ABFredrik&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-2179","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-nomination"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valberedning i XVIVO Perfusion AB (publ) - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valberedning i XVIVO Perfusion AB (publ) - XVIVO\" \/>\n<meta property=\"og:description\" content=\"F\u00f6ljande personer har utsetts att ing\u00e5 i XVIVO Perfusions valberedning inf\u00f6r \u00e5rsst\u00e4mman 2024: Henrik Blomquist, utsedd av Bure Equity ABFredrik...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-18T12:06:49+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/valberedning-i-xvivo-perfusion-ab-publ\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/valberedning-i-xvivo-perfusion-ab-publ\\\/\",\"name\":\"Valberedning i XVIVO Perfusion AB (publ) - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2023-09-29T04:00:00+00:00\",\"dateModified\":\"2023-10-18T12:06:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/valberedning-i-xvivo-perfusion-ab-publ\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/valberedning-i-xvivo-perfusion-ab-publ\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/valberedning-i-xvivo-perfusion-ab-publ\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valberedning i XVIVO Perfusion AB (publ)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valberedning i XVIVO Perfusion AB (publ) - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ\/","og_locale":"en_US","og_type":"article","og_title":"Valberedning i XVIVO Perfusion AB (publ) - XVIVO","og_description":"F\u00f6ljande personer har utsetts att ing\u00e5 i XVIVO Perfusions valberedning inf\u00f6r \u00e5rsst\u00e4mman 2024: Henrik Blomquist, utsedd av Bure Equity ABFredrik...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ\/","og_site_name":"United States","article_modified_time":"2023-10-18T12:06:49+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ\/","name":"Valberedning i XVIVO Perfusion AB (publ) - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2023-09-29T04:00:00+00:00","dateModified":"2023-10-18T12:06:49+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Valberedning i XVIVO Perfusion AB (publ)"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}